Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 1;275(6):1212-1220.
doi: 10.1097/SLA.0000000000004306. Epub 2020 Dec 3.

Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients

Moshe Lapidot  1 , Ritu R Gill  2 , Emanuele Mazzola  3 , Samuel Freyaldenhoven  1 , Scott J Swanson  1 , Michael T Jaklitsch  1 , David J Sugarbaker  4 , Raphael Bueno  1
Affiliations

Pleurectomy Decortication in the Treatment of Malignant Pleural Mesothelioma: Encouraging Results and Novel Prognostic Implications Based on Experience in 355 Consecutive Patients

Moshe Lapidot et al. Ann Surg. .

Abstract

Objective: We report a series of 355 consecutive patients treated over 9 years in a single institution with intended PDC.

Background: Surgery for MPM has shifted from extra-pleural pneumonectomy to PDC with the goal of MCR.

Methods: Clinical and outcome data were reviewed. Kaplan-Meier estimators and log rank test were used to compare the overall survival, and logistic regression models were used.

Results: MCR was achieved in 304. There were 223 males, median age was 69 and histology was epithelioid in 184. The 30 and 90-day mortality were 3.0% and 4.6%.Most complications were low grade. Prolonged air leak in 141, deep venous thrombosis in 64, Atrial fibrillation in 42, chylothorax in 24, Empyema in 23, pneumonia in 21, Hemothorax in 12 and pulmonary embolus in 8. Median/5-year survival were 20.7 months/17.9% in the intent-to-treat cohort and 23.2months/21.2% in the MCR group. The survivals were best for patients with Tlstage and epithelioid histology (69.8months/54.1%). In a multivariable analysis, factors that were found to be associated with longer patient overall survival included epithelioid histology, T stage, quantitative clinical stage/tumor volume staging, adjuvant chemotherapy, intraoperative heated chemo, female sex, and length of stay shorter than 14 days.

Conclusions: PDC is feasible with low mortality and is associated with manageable complication rates. 5-year survival of patients undergoing PDC with MCR in multi-modality setting is approaching 25% depending on quantitative and clinical stage, sex and histological subtype and is better than PDC without- MCR.

PubMed Disclaimer

Conflict of interest statement

The research did not receive any specific grant from funding agencies in the public, commercial or nonprofit sectors. The authors declare that there is no conflict of interest regarding the publication of this article.

References

    1. Beebe-Dimmer JL, Fryzek JP, Yee CL, et al. Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)–medicare investigation of treatment patterns and overall survival. Clin Epidemiol 2016; 8:743–750.
    1. Krug LM. An overview of chemotherapy for mesothelioma. Hematol Oncol Clin North Am 2005; 19:1117–1136.
    1. Kindler HL. Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 2008; 9:171–179.
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636–2644.
    1. Taioli E, Wolf AS, Camacho-Rivera M, et al. Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14, 228 patients. PLoS One 2015; 10:e0145039.

Publication types

LinkOut - more resources